Pitcairn Co. Sells 279 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Pitcairn Co. lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 10.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,329 shares of the medical research company’s stock after selling 279 shares during the quarter. Pitcairn Co.’s holdings in IQVIA were worth $552,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Capital Performance Advisors LLP bought a new stake in IQVIA during the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new stake in IQVIA during the third quarter worth about $28,000. Versant Capital Management Inc grew its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Barclays lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Robert W. Baird lowered their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Price Performance

Shares of NYSE IQV opened at $204.02 on Tuesday. The business has a fifty day moving average price of $221.96 and a two-hundred day moving average price of $226.98. The stock has a market capitalization of $37.03 billion, a PE ratio of 26.77, a P/E/G ratio of 2.08 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.